drugset / Trial / NCT00615212
Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is meant to assess potential inhibitory effects of GSK376501 on CYP450 isoenzymes 3A4, 2C8, 2C9. subjects will receive probe compounds and systemic levels of these substrates will be compared pre and post dosing of GSK376501.
Timeline
- Start
- 2008-01-02
- Primary completion
- 2008-02-15
- Completion
- 2008-02-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Flurbiprofen | Small molecule | 50 mg | Oral |
| Subject | GSK376501 | Small molecule | 75 mg | Oral |
| Subject | Midazolam | Small molecule | 5 mg | Oral |
| Subject | Rosiglitazone | Small molecule | 4 mg | Oral |